FDA Approval Alert: The Need-to-Know | Ribociclib/NSAI in HR+/HER2- Stage II-III Early Breast Cancer

In September 2024, the FDA approved ribociclib plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence.

Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
“Impactful” Data Presentations Raise Hope in the Breast Cancer Field
Video
Sep 19, 2024 8:00 PM
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer
Article
Sep 17, 2024 5:17 PM
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.